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Background: Our aim was to investigate the clinical efficacy and toxicity of metronomic adminis-
tration of low-dose cyclophosphamide (Cy) in lymphoma and sarcoma rat tumour models.
Methods: Adult inbred rats were challenged with lymphoma TACB and sarcoma E100 s.c. on day
0. Animals were divided into two groups: group I, control, injected with saline three times a week;
and group II, treated with Cy 10 mg/kg three times a week, from day 10 until the tumour was non-
palpable, or 5 mg/kg three times a week from day 7. Tumours were measured and animals were
weighed twice weekly. Periodic blood samples were taken for determination of urea, creatinine,
serum glutamic-oxaloacetic transaminase, lactate dehydrogenase and haematological parameters.
Results: The administration of low-dose Cy eradicated established rat lymphomas and sarcomas;
there was neither metastatic growth nor recurrence at primary sites for 100% of the lymphomas and
83% of the sarcomas. In addition, the treatment did not cause weight loss, and was devoid of haema-
tological, cardiac, hepatic and renal toxicity.
Conclusions: Metronomic administration of Cy at low doses on a thrice weekly schedule to already
grown rat lymphomas and sarcomas demonstrated itself to be a successful antitumour therapy that
did not cause weight loss and was devoid of haematological, cardiac, hepatic and renal toxicity.
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Introduction
One of the great advances in cancer treatment during last half
of the 20th century was the development and utilisation of
chemotherapeutic drugs. These compounds have demonstrated
antitumour efficacy through their damaging action against
cellular DNA, which prevents proliferation and, frequently,
drives the cell to its death. Since such an effect is only exerted
on a fraction of tumour cells, the administration of higher
drug doses are required to achieve better clinical results. How-
ever, the application of the highest drug doses tolerated by the
patient brings about the problem of drug toxicity. Thus, it is
mandatory to establish rest periods, which not only allow
regrowth of tumour cells but also growth of selected
therapy-resistant clones. After the successful first cycles of
treatment, tumours acquire resistance to the chemotherapeutic
drugs. Thus, the growth of those resistant cells involve the
development of more aggressive and malignant tumours.
In order to avoid the problems caused by traditional
chemotherapeutic treatments, several researchers, including
ourselves, recently began to search for new modalities of drug
administration oriented towards a more efficient and non-toxic
antitumoral and/or antimetastatic therapy. We have already
demonstrated that a single low dose of cyclophosphamide
(Cy), a treatment completely devoid of toxicity, inhibits the
growth of spontaneous and experimental metastasis of a rat
lymphoma, while it does not affect primary tumour growth
[1]. Such an effect would mainly be due to modulation of the
immune response [2–5]. These results proved that in our
tumour model, the targets of low-dose chemotherapy were the
immune cells and that metastatic cells were affected indirectly
by the drug.
On the other hand, Kerbel, Folkman and colleagues have
demonstrated the efficacy of some of the most widely used
chemotherapeutic drugs as antiangiogenic agents [6–9]. The
proposal implies that a change should be made with respect to
the rationale behind chemotherapy, involving a different
target. This new concept includes the possibility of treating
tumours that no longer respond to traditional chemotherapy.
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Results obtained at the clinical level [10] provide a point of
departure for future studies in this interesting area of cancer
therapy.
Our objective in this study was to investigate the possibility
of obtaining an antitumoral effect by the metronomic adminis-
tration of low-dose Cy. Another main focus of our work was to
determine the toxicity of the treatment. We report here the
effect of administration of (i) Cy 10 mg/kg on a thrice weekly
schedule, from day 10 until approximately day 60, on lym-
phoma TACB (L-TACB) growth; and (ii) Cy 5 mg/kg on the
same schedule, from day 7 until approximately day 30, on sar-
coma E100 (S-E100) growth, along with its toxicity.
Methods
Animals
Inbred adult IIM e/Fm and Fm-m rats (e and m, respectively) [11] from
the Facultad de Ciencias Me´dicas, Universidad Nacional de Rosario
breeding facilities, were used. Rats were fed with commercial chow and
water ad libitum, and were maintained in a 12 h light/dark cycle. All the
experiments were carried out during the first half of the light cycle.
The animals were treated in accordance with the guidelines issued by the
Canadian Council on Animal Care.
Drugs
Cy (Endoxan-Asta, Labinca SA, Argentina) was dissolved in sterile, dis-
tilled water to a concentration of 20 mg/ml.
Tumours
L-TACB is a poorly differentiated B-cell lymphoma, which arose spon-
taneously in an inbred e rat [12]. When L-TACB is injected subcu-
taneously, lymph nodes are the exclusive site of metastatic growth.
S-E100 is a fibrosarcoma that appeared spontaneously in an outbred
population of IIM rats in 1955 and is maintained by subcutaneous passage
in rats of the allogeneic inbred line m, with 100% lethality [13].
Experimental models
Adult e or m rats were challenged with L-TACB or S-E100, respectively,
subcutaneously by trocar, on day 0, and distributed as follows. L-TACB:
group I control rats (n = 7) were injected i.p. with saline three times a
week, from day 10 until animals were killed; and group II rats (n = 6)
were injected i.p. with Cy (10 mg/kg body weight) three times a week,
from day 10 until the day on which the tumour was no longer palpable.
S-E100: group I control animals (n = 12) were injected i.p. with saline
three times a week, from day 7 until animals were killed; and group II
rats (n = 12) were injected with Cy 5 mg/kg i.p., three times a week, from
day 7. In the case of the lymphoma tumour model, a third experimental
group was added (group III), in which naı¨ve animals (n = 4) were injected
with Cy, employing the same schedule and dose as in the respective
group II.
Tumours were measured twice weekly using a calliper. Tumour
volumes were calculated as follows: v = 0.4 (ab2), where v = volume
(cm3), a = largest diameter (cm) and b = smallest diameter (cm). Animals
were weighed weekly. On days 0, 20, 40 and 60, blood samples were
taken and each rat was subjected to an electrocardiogram (ECG). Group II
animals were clinically controlled and the appearance of tumour recur-
rences and metastasis was checked until the end of the experiment (day
150 for L-TACB and day 120 for S-E100).
Haematological and serological parameters
Blood and serum samples were obtained from animals belonging to all
experimental groups [L-TACB: group I (n = 7), group II (n = 6) and group
III (n = 4); S-E100: groups I and II (n = 4)] for the determination of haema-
tological and serological parameters, including haemoglobinemia, haema-
tocrit, total leukocyte count and proportion of white blood cell (WBC)
types (May Gru¨nwald–Giemsa colouration), and serum concentration of
urea (direct colorimetric method), creatinine (Jafee´ reaction), aspartate
aminotransferase (AST) and lactate dehydrogenase (LDH, E.C.1.1.1.27)
by the optimised ultraviolet method.
Electrocardiograms
The ECG DII derivation at a velocity of 50 mm/s was registered with
awake animals, employing a conventional electrocardiograph. Cardiac
rate, PRi (PR interval), QTi (QT interval) and AˆQRS (main ventricular
depolarisation vector) were measured, and the presence of arrhythmia or
other manifestations of myocardial lesions were analysed.
Statistical analyses
Analysis of variance and the Tukey–Kramer Multiple Comparison tests,
the Mann–Whitney non-parametric test and Student’s t-test (InStat,
GraphPad Software, Inc.) were used. Results were considered significant
if P-values were <0.05.
Results
Tumour growth assessment
After subcutaneous implantation of L-TACB or S-E100 in
e and m rats, respectively, tumours were allowed to grow to up
to 0.35 cm3 for L-TACB and 0.25 cm3 for S-E100 when Cy
treatment began. As can be seen in Figure 1A, the volume of
L-TACB tumours in control animals was significantly higher
than that in treated animals (P < 0.01) at day 20. At that time
point, while control animals were euthanised, the inhibition of
tumour growth began in treated rats. Complete regression of
the tumours was reached between days 30 and 60, and the
therapy was discontinued from the moment each tumour was
no longer palpable. Neither recurrences at the primary site nor
metastatic growth were observed until the end of the exper-
iment on day 150. Figure 1B shows the evolution of S-E100
tumour size after Cy treatment. The treated tumours increased
in size until day 14, when all the tumours began to regress. At
day 21 regression was complete for all the treated tumours and
therapy was discontinued. Nevertheless, by day 28 tumour
recurrence was observed at the primary site in two out of
12 animals, and despite re-entry into the treatment schedule for
10 more days, tumours continued growing until the animals
were killed. The rest of the treated animals were observed until
day 120 without showing recurrences. S-E100 control animals
were euthanised on day 20, their mean tumour volume being
significantly higher than that of treated rats (P < 0.0001).
Evaluation of toxicity
Body weight
Modification of body weight, a good indicator of general
health status, for both types of tumours showed no
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significant differences between control and treated animals
(Figure 2A and B), except for an increase in body weight on
day 20 in the L-TACB control group, which was probably due
to a concomitant rapid increase in tumour mass that did not
differ statistically from the weight of the L-TACB-bearing,
Cy-treated rats. There were no weight losses in the treated
groups of rats, including those without tumour and those trea-
ted with Cy. On the contrary, with the exception of isolated
non-statistically significant decreases, weights increased stea-
dily in both experiments.
Haematological parameters
The significant decrease in haemoglobin concentration in con-
trol L-TACB- and S-E100-bearing rats by day 20 compared
with basal values (P < 0.001 and <0.05, respectively) was not
observed in the corresponding treated groups (Figure 3A and
B), which maintained steady haemoglobin levels over time.
Also, in the group of rats without tumour but treated with Cy,
there was no evidence of any significant modification in
haemoglobinemia (Figure 3A). Haematocrit determination
yielded similar results for all the treated groups (Figure 3C
and D). Conversely, L-TACB and S-E100 control groups had
diminished haematocrit levels on day 20 compared with day 0
(P < 0.001 for L-TACB; P = not significant for S-E100). Total
leukocyte count did not show significant variation between the
groups treated for both tumour types, while control animals
presented an increase in total leukocytes for L-TACB
(P < 0.001) and S-E100 (P = 0.057) (Figure 3E and F). On the
other hand, animals belonging to the group without tumour
but treated with Cy showed a significant decrease in WBC
count to  35% of basal values (P < 0.05). The proportion of
each WBC type to total leukocytes also showed variation
(mainly for neutrophils and lymphocytes) in the experiments.
By day 20 and/or 40, L-TACB and S-E100 Cy-treated rats
showed an increase in neutrophils and a decrease in lympho-
cytes, albeit to different degrees, with both tending to
normalise towards day 60 (Table 1). The same tendency was
observed for control rats at day 20. In the Cy-treated group
Figure 2. Evolution of body weight during treatment of established
lymphoma TACB (L-TACB)-bearing rats (A) and sarcoma E100
(S-E100)-bearing rats (B) with low-dose cyclophosphamide. No body
weight losses were detected in either tumour model. Data shown
represent mean values ± SEM of body weight (g).
Figure 1. Regression of established tumours by chronic administration of
low-dose cyclophosphamide (Cy). (A) Lymphoma TACB (L-TACB),
control versus tumour + Cy (P < 0.001). (B) Sarcoma E100 (S-E100),
control versus tumour + Cy (P < 0.001). Data shown represent mean
values ± SEM (standard error of the mean).
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without tumour, no important modifications in the proportion
of both WBC types were observed (Table 1).
Serologic parameters
Concentration of serum urea showed no significant variation,
either in control or treated groups for L-TACB-bearing rats
(Figure 4A). The same result was obtained for creatinine
serum concentration, determined only in samples from
L-TACB tumour models (Figure 4C). In the S-E100 tumour
model, urea concentration increased at day 20 in both exper-
imental groups (Figure 4B), with the level in the control
group being higher than that in the treated group (P = 0.053).
Rejection of the tumours was accompanied on days 40 and 60
by a normalisation of serum urea concentration.
A striking elevation of AST concentration was observed
at day 20 in L-TACB control animals (>15-fold increase)
and S-E100 control animals (5-fold increase). While serum
samples of S-E100 Cy-treated rats did not show any significant
Figure 3. (A and B) Haemoglobin concentration (mean ± SEM) in lymphoma TACB (L-TACB)- and sarcoma E100 (S-E100)-treated animals,
respectively. Control L-TACB and S-E100 rats, day 0 versus day 20: P < 0.001 and P < 0.05, respectively. (C and D) Haematocrit values [median (range)]
in L-TACB- and S-E100-treated animals, respectively. Control L-TACB rats, day 0 versus day 20: P < 0.001. (E and F) Total leukocyte count
[median (range)] in L-TACB- and S-E100-treated animals, respectively. Control L-TACB and S-E100 rats, day 0 versus day 20: P < 0.001 and P = 0.057,
respectively; naı¨ve rats + Cy, day 0 versus days 40 and 60: P < 0.05. WBC, White blood cell count.
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Table 1. Evolution of the proportion of neutrophils and lymphocytes to total leukocytes after metronomic dosing with Cy in
L-TACB and S-E100 tumour models
Group Day Percentage of cells [median (range)]
L-TACB S-E100
Neutrophils Lymphocytes Neutrophils Lymphocytes
Control 0 25 (18–26) 68 (63–74) 22.5 (20–25) 70 (65–71)
L-TACB (n = 7) 20 27 (21–41) 54 (37–69) 27 (14–37) 66.5 (55–78)
S-E100 (n = 4)
Tumour + Cy 0 25.5 (19–34) 63 (55–73) 16.5 (14–21) 77.5 (76–80)
L-TACB (n = 6) 20 35 (20–45) 53.5 (42–73) 25 (17–41) 67.5(58–77)
S-E100 (n = 4) 40 47 (39–48) 47.5 (40–57) 27 (15–43) 65 (53–76)
60 34.5 (27–27) 67 (53–70) 21.5 (15–24) 70.5 (65–80)
Cy 0 33.5 (26–41) 58.5 (50–71)
(n = 4) 20 27 (23–34) 64.5 (58–70)
40 31 (24–40) 58 (50–62)
60 28.5 (20–35) 59 (50–63)
Cy, cyclophosphamide; L-TACB, lymphoma TACB; S-E100, sarcoma E100.
Figure 4. (A and C) Urea and creatinine serum concentration (mean ± SEM), respectively, in the lymphoma TACB (L-TACB) tumour model. (B) Serum
urea concentrations in the sarcoma E100 (S-E100) tumour model. Day 20, control versus tumour + Cy: P = 0.053.
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variation in AST levels throughout the experiment, samples
from L-TACB Cy-treated rats showed a transient, significant
elevation of AST concentration (P < 0.05) on day 20 compared
with basal values, which returned to normal on day 40 (Figure
5A and B). The modifications observed in serum LDH concen-
tration were similar in both tumour models, albeit at different
levels. Significant elevations were seen in serum LDH from
both control groups at day 20 compared with basal values. The
treatment of both tumour types diminished LDH levels by day
20 compared with those of control rats (Figure 5C and D), with
values that were approaching statistical significance. Normality
in LDH levels was finally reached on day 60. Interestingly,
serum samples from the group without tumour but treated with
Cy showed a significant decrease in LDH levels (P < 0.05) by
days 40 and 60 (Figure 5C).
Electrocardiograms
Neither modifications of PRi, QTi and AˆQRS nor manifes-
tations of myocardial lesions or arrhythmia were observed in
control or treated rats. All the animals and experimental
groups showed a similar ECG (data not shown).
Discussion
Historically, chemotherapy regimens have been controversial:
which way should the scale be tipped between efficacy in
tumour killing and lack of toxicity? On one hand, there is the
ability of chemotherapeutic drugs to disrupt the DNA of
tumour cells, rendering them unable to replicate and finally
killing them, the befitting corollary being ‘the higher the dose
the better’ [14]. On the other hand, toxicity is expressed at
several organ sites, which not only diminishes quality of
patient life but also conspires against a good resolution of the
cancer treatment, adding illness to that which already exists
[15–17]. The introduction of maximum tolerated doses in
usual treatment protocols made it necessary to impose periods
of rest between cycles of therapy. During such rest periods,
recovery of ‘good’ cells is frequently accompanied by recov-
ery of ‘bad’ cells, i.e. tumour cells resistant to the drug cell
killing effect. The possibility of finding a treatment modality
that avoids toxicity without diminishing effectiveness is still a
matter for study and discussion. Several groups, including
ours, have begun to address this issue. The experimental
findings of Browder [7], Klement [6, 8] and Man [9] and
colleagues successfully introduced a novel strategy for cancer
Figure 5. (A and B) AST serum concentration (mean ± SEM) in lymphoma TACB (L-TACB)- and sarcoma E100 (S-E100)-treated animals, respectively.
L-TACB + Cy rats, day 0 versus day 20: P < 0.05; day 20, control versus tumour + Cy: P < 0.001. (C and D) LDH serum concentration (mean ± SEM) in
L-TACB- and S-E100-treated animals, respectively. Cy-treated L-TACB rats and L-TACB and S-E100 control groups, day 0 versus day 20: P < 0.05.
Naı¨ve rats + Cy, day 0 versus days 40 and 60: P < 0.05.
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treatment. The novel component comprised a cell target
switch, which now aims towards the genetically stable tumour
endothelial cells, along with a change in the schedule and
dose of drug administration, thereby introducing metronomic
chemotherapy [18]. We have previously demonstrated the
effectiveness of a unique low dose of Cy, with no toxicity, in
inhibiting lymphoma metastasis through modulation of the
immune response [1–5]. In this study, we wished to determine
whether the same low dose of Cy, administered chronically,
could achieve an antitumour effect while maintaining a lack
of toxicity. We studied not only the evolution of body weight,
a suitable indicator of health status, but also serological and
haematological parameters alongside ECG determinations.
The experimental models were designed to resemble the
clinical situation of a patient with a recently detected tumour
(not too large, but large enough to be easily detected) who
begins therapy immediately after being diagnosed. Metro-
nomic therapy began after 10 and 7 days of the tumour chal-
lenge, for L-TACB and S-E100, respectively. The response of
L-TACB-bearing rats to treatment was complete in 100% of
the animals, achieving total regression between days 30 and
60. Importantly, neither recurrences nor metastases were
detected until the end of the experiment. The behaviour of
S-E100 after Cy treatment was similar to that of L-TACB
until day 28, when tumour growth at the primary site resumed
in two out of 12 rats. The rest of the animals remained recur-
rence-free until the end of the experiment. These results,
obtained with tumour types and species different from those
assayed up to now, provide additional experimental evidence
for the antitumour effect of metronomic therapy. The demon-
stration that different kinds of tumours can be eliminated or
significantly diminished [6–10] by chronic administration of
low doses of very different kinds of chemotherapeutic drugs
[19] increases the likelihood of successful treatment of human
cancer. It also encourages the development of phase I and II
clinical trials for different cancer types using different drugs,
which, ultimately, will determine the efficacy of metronomic
therapy for the treatment of human cancers.
Other authors have demonstrated clearly the antiangiogenic
nature of the mechanism of action of several drugs adminis-
tered by metronomic dosing. Moreover, the combination of
such treatment with specific antiangiogenic reagents increased
significantly the observed antitumour effect of metronomic dos-
ing [6–8, 20, 21]. Hence, the antitumour effect described
herein is probably due to an antiangiogenic mechanism. Some
recent findings by Mauceri et al. [22] support this hypothesis.
She found that the addition of Cy to angiostatin, an internal
fragment of plasminogen with antiangiogenic properties that is
generally secreted by tumours [23], produced inhibition of tube
formation. Moreover, recent preliminary results, from our lab-
oratory, utilising the Matrigel plug angiogenesis assay in e rats
showed an antiangiogenic effect exerted by four injections of
Cy (10 mg/kg) administered over 6 days. Nevertheless, we do
not dismiss the existence of other mechanisms contributing to
the antitumour effect, mainly the modulation of the immune
response, as we have demonstrated for the antimetastatic effect
of single low-dose Cy in the L-TACB tumour model [2–5].
The recurrence of the tumour in 17% of the Cy-treated, S-
E100-bearing rats suggested that, in this case, the cell target of
Cy would not be the genetically stable endothelial cells, which
in all likelihood would not generate drug resistance. Future
studies will address this important matter.
Determination of body weight showed no weight loss in
either treatment group for each tumour model. The body
weight of treated animals increased steadily, with the excep-
tion of transient, non-significant decreases. Concomitantly,
animals were monitored for the appearance of any other clini-
cal sign of drug toxicity, which never appeared.
From a haematological point of view, determinations of the
haematological parameters throughout the study demonstrated
the lack of toxicity of the treatment. Haemoglobin concen-
tration and haematocrit did not suffer variation in any of the
Cy-treated groups throughout the experiments, while in both
control groups there were significant decreases in both values.
Also, while the WBC count increased significantly with tumour
growth, a significant decrease was observed in the group of
naı¨ve Cy-treated rats. These opposite effects caused by tumour
growth and Cy treatment, respectively, might account for the
lack of WBC changes observed in Cy-treated L-TACB- and
S-E100-bearing rats. The altered WBC proportions observed in
treated tumour-bearing rats, namely an increase in neutrophils
and a decrease in lymphocytes, tended to return to basal values
by day 60. Such changes are mainly due to tumour growth,
because naı¨ve rats treated only with Cy showed no important
modifications to these proportions. Moreover, the Cy-treated
tumour-bearing rats returned to normal values between days 40
and 60, despite continuation of chemotherapy.
Similarly, the evaluation of biochemical parameters showed
a lack of renal, hepatic or cardiac toxicity with the treatment.
Serum concentrations of urea and creatinine in L-TACB-
bearing rats remained unaltered, while in the S-E100 tumour
model, the significant increase in serum urea in control rats,
caused by tumour growth, was moderated by the treatment.
Cy-treated S-E100-bearing rats showed normalised uraemia by
days 40–60; therefore, there was no renal toxicity when
measured using these parameters.
The growth of L-TACB or S-E100 was accompanied by a
striking elevation in AST concentration. AST is an enzyme pre-
sent in high concentrations in tissues with high metabolic
activity. Elevated levels of AST have been correlated with cer-
tain malignancies [24]. Severely damaged or dead cells release
AST into the blood in quantities directly proportional to the
amount of tissue damage [25]. Interestingly, the treatment
administered herein did not modify the normal enzyme levels
in S-E100-treated rats. Besides, in L-TACB Cy-treated rats
there was a transient increase in AST concentration at day 20;
an increase that, nevertheless, was significantly lower than that
of control rats (P < 0.01), returning to normal levels by day 40.
Many tissues, including the liver, red blood cells and
the brain, produce LDH, an enzyme normally found in the
blood. The fact that tumour growth is frequently associated
with an increase in LDH serum levels is already known,
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and this protein can be considered as a tumour marker [26,
27]. Also, LDH, as well as AST, are protein markers associ-
ated with different types and degrees of cardiac damage [28].
The significant increases in LDH serum concentration found
in control rats belonging to both tumour models were moder-
ated by the treatment at day 20 and continued to decrease
towards day 60. The augmentation of serum LDH during
tumour growth would probably be compensated for by the
decrease observed during Cy treatment in naı¨ve rats. The AST
and LDH results obtained herein indicate a lack of hepatic and
cardiac toxicity with the treatment. Moreover, there were no
changes in ECG results during the treatment, a fact that con-
firmed the absence of gross cardiac alterations.
In summary, metronomic administration of Cy at low doses
on a thrice weekly schedule to already grown rat lymphomas
and sarcomas was demonstrated to be a successful antitumour
therapy that, interestingly, was devoid of toxicity. Further
studies will help to clarify the mechanism of action and what
type of cells are being targeted by this chronic chemotherapy.
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